KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Share-based Compensation (2018 - 2025)

Moderna (MRNA) has disclosed Share-based Compensation for 8 consecutive years, with $113.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 8.65% to $113.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $483.0 million through Dec 2025, up 12.59% year-over-year, with the annual reading at $483.0 million for FY2025, 12.59% up from the prior year.
  • Share-based Compensation for Q4 2025 was $113.0 million at Moderna, down from $125.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $130.0 million in Q2 2025, with the low at $30.0 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $79.2 million, with a median of $76.0 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 81.82% in 2021, then increased 8.65% in 2025.
  • Over 5 years, Share-based Compensation stood at $37.0 million in 2021, then skyrocketed by 67.57% to $62.0 million in 2022, then grew by 27.42% to $79.0 million in 2023, then surged by 31.65% to $104.0 million in 2024, then increased by 8.65% to $113.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $113.0 million, $125.0 million, and $130.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.